James W Baurley
Biographic Data
| ID | 5484979 |
|---|---|
| NAME | James W Baurley |
| GIVEN NAMES | James W |
| FAMILY NAME | Baurley |
| SIGNATURE | BAURLEY J W |
| AFFILIATIONS | BioRealm (United States) |
| ORCID | 0000-0003-4116-7723 |
| VERIFIED | Yes |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 4 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2015 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Bayesian Machine Learning Tools for Alcohol Use Disorder Research
Alcohol use disorder (AUD) research faces significant challenges in capturing individual heterogeneity and complex temporal patterns in drinking behaviors. Standard statistical methods fail to account for within-person variability and between-person differences, while existing machine learning algorithms are not designed for hierarchical, longitudinal data structures common in AUD research. We developed a comprehensive R package implementing 30 B…
Assessing Opioid Use Disorder Treatments in Trials Subject to Non-Adherence via a Functional Generalized Linear Mixed-Effects Model
The opioid crisis in the United States poses a major threat to public health due to psychiatric and infectious disease comorbidities and death due to opioid use disorder (OUD). OUD is characterized by patterns of opioid misuse leading to persistent heavy use and overdose. The standard of care for treatment of OUD is medication-assisted treatment, in combination with behavioral therapy. Medications for opioid use disorder have been shown to improv…
Effects of Buprenorphine Dose and Therapeutic Engagement on Illicit Opiate Use in Opioid Use Disorder Treatment Trials
The impact of agonist dose and of physician, staff and patient engagement on treatment have not been evaluated together in an analysis of treatment for opioid use disorder. Our hypotheses were that greater agonist dose and therapeutic engagement would be associated with reduced illicit opiate use in a time-dependent manner. Publicly-available treatment data from six buprenorphine efficacy and safety trials from the Federally-supported Clinical Tr…
Total Exposure Study Analysis consortium
The Total Exposure Study was a stratified, multi-center, cross-sectional study designed to estimate levels of biomarkers of tobacco-specific and non-specific exposure and of potential harm in U.S. adult current cigarette smokers (≥one manufactured cigarette per day over the last year) and tobacco product non-users (no smoking or use of any nicotine containing products over the last 5 years). The study was designed and sponsored by a tobacco compa…
No prominent works on this page.
Total Exposure Study Analysis consortium
The Total Exposure Study was a stratified, multi-center, cross-sectional study designed to estimate levels of biomarkers of tobacco-specific and non-specific exposure and of potential harm in U.S. adult current cigarette smokers (≥one manufactured cigarette per day over the last year) and tobacco product non-users (no smoking or use of any nicotine containing products over the last 5 years). The study was designed and sponsored by a tobacco compa…
Assessing Opioid Use Disorder Treatments in Trials Subject to Non-Adherence via a Functional Generalized Linear Mixed-Effects Model
The opioid crisis in the United States poses a major threat to public health due to psychiatric and infectious disease comorbidities and death due to opioid use disorder (OUD). OUD is characterized by patterns of opioid misuse leading to persistent heavy use and overdose. The standard of care for treatment of OUD is medication-assisted treatment, in combination with behavioral therapy. Medications for opioid use disorder have been shown to improv…
Effects of Buprenorphine Dose and Therapeutic Engagement on Illicit Opiate Use in Opioid Use Disorder Treatment Trials
The impact of agonist dose and of physician, staff and patient engagement on treatment have not been evaluated together in an analysis of treatment for opioid use disorder. Our hypotheses were that greater agonist dose and therapeutic engagement would be associated with reduced illicit opiate use in a time-dependent manner. Publicly-available treatment data from six buprenorphine efficacy and safety trials from the Federally-supported Clinical Tr…
Bayesian Machine Learning Tools for Alcohol Use Disorder Research
Alcohol use disorder (AUD) research faces significant challenges in capturing individual heterogeneity and complex temporal patterns in drinking behaviors. Standard statistical methods fail to account for within-person variability and between-person differences, while existing machine learning algorithms are not designed for hierarchical, longitudinal data structures common in AUD research. We developed a comprehensive R package implementing 30 B…
Internal Medicine (3 works) · Medicine (3 works) · Substance Abuse Treatment and Outcomes (3 works) · Buprenorphine (2 works) · Opioid (2 works) · Opioid use disorder (2 works) · Opioid Use Disorder Treatment (2 works) · Psychiatry (2 works) · Public health (2 works) · Alcohol consumption (1 work)